127 related articles for article (PubMed ID: 20210803)
21. Expression of SPARC in tongue carcinoma of stage II is associated with poor prognosis: an immunohistochemical study of 86 cases.
Kato Y; Nagashima Y; Baba Y; Kawano T; Furukawa M; Kubota A; Yanoma S; Imagawa-Ishiguro Y; Satake K; Taguchi T; Hata R; Mochimatsu I; Aoki I; Kameda Y; Inayama Y; Tsukuda M
Int J Mol Med; 2005 Aug; 16(2):263-8. PubMed ID: 16012759
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of the X-linked inhibitor of apoptosis protein for invasive ductal breast cancer with triple-negative phenotype.
Wang J; Liu Y; Ji R; Gu Q; Zhao X; Liu Y; Sun B
Hum Pathol; 2010 Aug; 41(8):1186-95. PubMed ID: 20381828
[TBL] [Abstract][Full Text] [Related]
23. Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis.
Dolled-Filhart M; Camp RL; Kowalski DP; Smith BL; Rimm DL
Clin Cancer Res; 2003 Feb; 9(2):594-600. PubMed ID: 12576423
[TBL] [Abstract][Full Text] [Related]
24. Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity.
Viale G; Rotmensz N; Maisonneuve P; Bottiglieri L; Montagna E; Luini A; Veronesi P; Intra M; Torrisi R; Cardillo A; Campagnoli E; Goldhirsch A; Colleoni M
Breast Cancer Res Treat; 2009 Jul; 116(2):317-28. PubMed ID: 18839307
[TBL] [Abstract][Full Text] [Related]
25. Motility-related protein-1 (MRP-1/CD9) reduction as a factor of poor prognosis in breast cancer.
Miyake M; Nakano K; Itoi SI; Koh T; Taki T
Cancer Res; 1996 Mar; 56(6):1244-9. PubMed ID: 8640807
[TBL] [Abstract][Full Text] [Related]
26. Concomitant expression of epithelial-mesenchymal transition biomarkers in breast ductal carcinoma: association with progression.
Logullo AF; Nonogaki S; Pasini FS; Osório CA; Soares FA; Brentani MM
Oncol Rep; 2010 Feb; 23(2):313-20. PubMed ID: 20043090
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma.
Esteva FJ; Sahin AA; Smith TL; Yang Y; Pusztai L; Nahta R; Buchholz TA; Buzdar AU; Hortobagyi GN; Bacus SS
Cancer; 2004 Feb; 100(3):499-506. PubMed ID: 14745865
[TBL] [Abstract][Full Text] [Related]
28. Microsatellite alterations on human chromosome 11 in in situ and invasive breast cancer: a microdissection microsatellite analysis and correlation with p53, ER (estrogen receptor), and PR (progesterone receptor) protein immunoreactivity.
Shen KL; Yang LS; Hsieh HF; Chen CJ; Yu JC; Tsai NM; Harn HJ
J Surg Oncol; 2000 Jun; 74(2):100-7. PubMed ID: 10914818
[TBL] [Abstract][Full Text] [Related]
29. [Proliferation index and its prognostic value in invasive ductal breast carcinoma].
Falco M
Ann Acad Med Stetin; 2009; 55(1):22-30. PubMed ID: 20349588
[TBL] [Abstract][Full Text] [Related]
30. A sialoglycoprotein (LEA.135) associated with favourable prognosis of patients with lymph node-negative primary breast carcinoma.
Imam SA; Chaiwun B; Wang MJ; Morris MM; Groshen SG; Neville AM; Torloni H; Cote RJ; Taylor CR
Anticancer Res; 1996; 16(5B):3043-8. PubMed ID: 8920764
[TBL] [Abstract][Full Text] [Related]
31. Thermography. Its relation to pathologic characteristics, vascularity, proliferation rate, and survival of patients with invasive ductal carcinoma of the breast.
Sterns EE; Zee B; SenGupta S; Saunders FW
Cancer; 1996 Apr; 77(7):1324-8. PubMed ID: 8608510
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of MAGE-A9 predicts unfavorable outcome in breast cancer.
Xu X; Tang X; Lu M; Tang Q; Zhang H; Zhu H; Xu N; Zhang D; Xiong L; Mao Y; Zhu J
Exp Mol Pathol; 2014 Dec; 97(3):579-84. PubMed ID: 25445503
[TBL] [Abstract][Full Text] [Related]
33. Stromal remodeling and SPARC (secreted protein acid rich in cysteine) expression in invasive ductal carcinomas of the breast.
Barth PJ; Moll R; Ramaswamy A
Virchows Arch; 2005 May; 446(5):532-6. PubMed ID: 15838642
[TBL] [Abstract][Full Text] [Related]
34. Expression of secreted protein acidic and rich in cysteine is an independent prognostic indicator of a poor clinical outcome in oropharyngeal carcinoma patients.
Yoshida S; Wakisaka N; Kondo S; Moriyama-Kita M; Hirai N; Endo K; Tsuji A; Nakanishi Y; Murono S; Yoshizaki T
Acta Otolaryngol; 2016; 136(2):189-94. PubMed ID: 26523779
[TBL] [Abstract][Full Text] [Related]
35. Correlation Between Expression of Twist and Podoplanin in Ductal Breast Carcinoma.
Grzegrzolka J; Wojtyra P; Biala M; Piotrowska A; Gomulkiewicz A; Rys J; Podhorska-Okolow M; Dziegiel P
Anticancer Res; 2017 Oct; 37(10):5485-5493. PubMed ID: 28982860
[TBL] [Abstract][Full Text] [Related]
36. The relationship between SPARC expression in primary tumor and metastatic lymph node of resected pancreatic cancer patients and patients' survival.
Yu XZ; Guo ZY; Di Y; Yang F; Ouyang Q; Fu DL; Jin C
Hepatobiliary Pancreat Dis Int; 2017 Feb; 16(1):104-109. PubMed ID: 28119265
[TBL] [Abstract][Full Text] [Related]
37. The clinical significance of secreted protein acidic and rich in cysteine expression in breast cancer tissue and its association with prognosis.
Guo W; Zhang M; Chen Y; Guo S
J Cancer Res Ther; 2017; 13(5):833-836. PubMed ID: 29237913
[TBL] [Abstract][Full Text] [Related]
38. Metaplastic breast cancer: a comparison between the most common histologies with poor immunohistochemistry factors.
Barquet-Muñoz SA; Villarreal-Colin SP; Herrera-Montalvo LA; Soto-Reyes E; Pérez-Plasencia C; Coronel-Martínez J; Pérez-Montiel D; Vázquez-Romo R; Cantú de León D
BMC Cancer; 2015 Feb; 15():75. PubMed ID: 25881163
[TBL] [Abstract][Full Text] [Related]
39. Expression of osteopontin and osteonectin in breast cancer.
Kim YW; Park YK; Lee J; Ko SW; Yang MH
J Korean Med Sci; 1998 Dec; 13(6):652-7. PubMed ID: 9886175
[TBL] [Abstract][Full Text] [Related]
40. Prognostic impact of tumoral and/or peri-tumoral stromal SPARC expressions after surgery in patients with biliary tract cancer.
Nakashima S; Kobayashi S; Sakai D; Tomokuni A; Tomimaru Y; Hama N; Wada H; Kawamoto K; Marubashi S; Eguchi H; Matsuura N; Doki Y; Mori M; Nagano H
J Surg Oncol; 2014 Dec; 110(8):1016-22. PubMed ID: 25155283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
